New Pyridopyrimidone Derivatives: Synthesis, Molecular Docking Studies, and Potential Anticancer Activity


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

A new series of pyrido[2,3-d]pyrimidones incorporated pyrazoles and fused triazoles are synthesized and tested in vitro for cytotoxic effect against cancer cell lines: HePG-2, HCT-116, MCF-7, PC-3, and A-549. Their inhibition of protein kinase is assessed. The highest growth inhibitory (IC50 0.3 µM) effect is determined for one of compounds as compared with doxorubicin (IC50 0.6 µM). A modeling study is performed for approaching the compounds mode of binding and their similarity with the positive control drugs.

Sobre autores

N. Khalifa

Pharmaceutical Chemistry Department, Drug Exploration and Development Chair (DEDC), College of Pharmacy; Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Division

Autor responsável pela correspondência
Email: nkhalifa.c@ksu.edu.sa
Arábia Saudita, Riyadh, 11451; Giza, Cairo, 12622

H. Alkahtani

Pharmaceutical Chemistry Department, College of Pharmacy

Email: nkhalifa.c@ksu.edu.sa
Arábia Saudita, Riyadh, 11451

M. Al-Omar

Pharmaceutical Chemistry Department, Drug Exploration and Development Chair (DEDC), College of Pharmacy; Pharmaceutical Chemistry Department, College of Pharmacy

Email: nkhalifa.c@ksu.edu.sa
Arábia Saudita, Riyadh, 11451; Riyadh, 11451

A. Bakheit

Pharmaceutical Chemistry Department, College of Pharmacy; Chemistry Department, Faculty of Science and Technology

Email: nkhalifa.c@ksu.edu.sa
Arábia Saudita, Riyadh, 11451; Khartoum


Declaração de direitos autorais © Pleiades Publishing, Ltd., 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies